B Cells Promote Tumor Progression via STAT3 Regulated-Angiogenesis

PLoS ONE

Volumn 8, Issue 5, 2013, Pages

  Yang, Chunmei ^a   Lee, Heehyoung ^a   Pal, Sumanta ^a   Jove, Veronica ^a   Deng, Jiehui ^a   Zhang, Wang ^a   Hoon, Dave S B ^b   Wakabayashi, Mark ^a   Forman, Stephen ^a   Yu, Hua ^a,c  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b JOHN WAYNE CANCER INSTITUTE   (United States)

^c Center for Translational Medicine   (China)

Author keywords

[No Author keywords available]

Indexed keywords

STAT3 PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC THERAPY; ARTICLE; B LYMPHOCYTE; CANCER GROWTH; CONTROLLED STUDY; DRUG TARGETING; EX VIVO STUDY; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; LEWIS CARCINOMA; LYMPHOCYTE FUNCTION; MALE; MELANOMA B16; MOUSE; NONHUMAN; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; TUMOR VASCULARIZATION;

ANIMALS; B-LYMPHOCYTES; BLOTTING, WESTERN; CELL LINE, TUMOR; DISEASE PROGRESSION; ENDOTHELIAL CELLS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; MICE, 129 STRAIN; MICE, INBRED C57BL; MICE, KNOCKOUT; MICROSCOPY, CONFOCAL; NEOPLASMS, EXPERIMENTAL; NEOVASCULARIZATION, PATHOLOGIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; TUMOR BURDEN;

EID: 84878448880     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0064159     Document Type: Article

References (53)

1. Milne K, Kobel M, Kalloger SE, Barnes RO, Gao D, et al. (2009) Systematic analysis of immune infiltrates in high-grade serous ovarian cancer reveals CD20, FoxP3 and TIA-1 as positive prognostic factors. PLoS One 4: e6412.
2. Pages F, Berger A, Camus M, Sanchez-Cabo F, Costes A, et al. (2005) Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med 353: 2654-2666.
3. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, et al. (2006) Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313: 1960-1964.
4. Tan TT, Coussens LM, (2007) Humoral immunity, inflammation and cancer. Curr Opin Immunol 19: 209-216.
5. Ohri CM, Shikotra A, Green RH, Waller DA, Bradding P, (2009) Macrophages within NSCLC tumour islets are predominantly of a cytotoxic M1 phenotype associated with extended survival. Eur Respir J 33: 118-126.
6. Sato E, Olson SH, Ahn J, Bundy B, Nishikawa H, et al. (2005) Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci U S A 102: 18538-18543.
7. Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, et al. (2004) Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 10: 942-949.
8. Hamanishi J, Mandai M, Iwasaki M, Okazaki T, Tanaka Y, et al. (2007) Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proc Natl Acad Sci U S A 104: 3360-3365.
9. Gabitass RF, Annels NE, Stocken DD, Pandha HA, Middleton GW, (2011) Elevated myeloid-derived suppressor cells in pancreatic, esophageal and gastric cancer are an independent prognostic factor and are associated with significant elevation of the Th2 cytokine interleukin-13. Cancer Immunol Immunother 60: 1419-1430.
10. Nelson BH, (2010) CD20+ B cells: the other tumor-infiltrating lymphocytes. J Immunol 185: 4977-4982.
11. Al-Shibli KI, Donnem T, Al-Saad S, Persson M, Bremnes RM, et al. (2008) Prognostic effect of epithelial and stromal lymphocyte infiltration in non-small cell lung cancer. Clin Cancer Res 14: 5220-5227.
12. Lim KH, Telisinghe PU, Abdullah MS, Ramasamy R, (2010) Possible significance of differences in proportions of cytotoxic T cells and B-lineage cells in the tumour-infiltrating lymphocytes of typical and atypical medullary carcinomas of the breast. Cancer Immun 10: 3.
13. de Visser KE, Korets LV, Coussens LM, (2005) De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent. Cancer Cell 7: 411-423.
14. Andreu P, Johansson M, Affara NI, Pucci F, Tan T, et al. (2010) FcRgamma activation regulates inflammation-associated squamous carcinogenesis. Cancer Cell 17: 121-134.
15. Mantovani A, (2011) B cells and macrophages in cancer: yin and yang. Nat Med 17: 285-286.
16. Ammirante M, Luo JL, Grivennikov S, Nedospasov S, Karin M, (2010) B-cell-derived lymphotoxin promotes castration-resistant prostate cancer. Nature 464: 302-305.
17. Kumar S, Mohan A, Guleria R, (2009) Prognostic implications of circulating anti-p53 antibodies in lung cancer-a review. Eur J Cancer Care (Engl) 18: 248-254.
18. Yang C, Lee H, Jove V, Deng J, Zhang W, et al. (2013) Prognostic significance of B-cells and pSTAT3 in patients with ovarian cancer. PLoS One 8: e54029.
19. Chung AS, Lee J, Ferrara N, (2010) Targeting the tumour vasculature: insights from physiological angiogenesis. Nat Rev Cancer 10: 505-514.
20. Hanahan D, Weinberg RA, (2011) Hallmarks of cancer: the next generation. Cell 144: 646-674.
21. Carmeliet P, Jain RK, (2011) Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases. Nat Rev Drug Discov 10: 417-427.
22. Fidler IJ, Ellis LM, (1994) The implications of angiogenesis for the biology and therapy of cancer metastasis. Cell 79: 185-188.
23. Zumsteg A, Christofori G, (2009) Corrupt policemen: inflammatory cells promote tumor angiogenesis. Curr Opin Oncol 21: 60-70.
24. Pietras K, Ostman A, (2010) Hallmarks of cancer: interactions with the tumor stroma. Exp Cell Res 316: 1324-1331.
25. Fidler IJ, (2003) The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nat Rev Cancer 3: 453-458.
26. Weis SM, Cheresh DA, (2011) Tumor angiogenesis: molecular pathways and therapeutic targets. Nat Med 17: 1359-1370.
27. Wei D, Le X, Zheng L, Wang L, Frey JA, et al. (2003) Stat3 activation regulates the expression of vascular endothelial growth factor and human pancreatic cancer angiogenesis and metastasis. Oncogene 22: 319-329.
28. Niu G, Wright KL, Huang M, Song L, Haura E, et al. (2002) Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene 21: 2000-2008.
29. Gong W, Wang L, Yao JC, Ajani JA, Wei D, et al. (2005) Expression of activated signal transducer and activator of transcription 3 predicts expression of vascular endothelial growth factor in and angiogenic phenotype of human gastric cancer. Clin Cancer Res 11: 1386-1393.
30. Kujawski M, Kortylewski M, Lee H, Herrmann A, Kay H, et al. (2008) Stat3 mediates myeloid cell-dependent tumor angiogenesis in mice. J Clin Invest 118: 3367-3377.
31. Huang S, Pettaway CA, Uehara H, Bucana CD, Fidler IJ, (2001) Blockade of NF-kappaB activity in human prostate cancer cells is associated with suppression of angiogenesis, invasion, and metastasis. Oncogene 20: 4188-4197.
32. Kim SJ, Uehara H, Karashima T, Shepherd DL, Killion JJ, et al. (2003) Blockade of epidermal growth factor receptor signaling in tumor cells and tumor-associated endothelial cells for therapy of androgen-independent human prostate cancer growing in the bone of nude mice. Clin Cancer Res 9: 1200-1210.
33. Langley RR, Fan D, Tsan RZ, Rebhun R, He J, et al. (2004) Activation of the platelet-derived growth factor-receptor enhances survival of murine bone endothelial cells. Cancer Res 64: 3727-3730.
34. Lee H, Herrmann A, Deng JH, Kujawski M, Niu G, et al. (2009) Persistently activated Stat3 maintains constitutive NF-kappaB activity in tumors. Cancer Cell 15: 283-293.
35. Kortylewski M, Swiderski P, Herrmann A, Wang L, Kowolik C, et al. (2009) In vivo delivery of siRNA to immune cells by conjugation to a TLR9 agonist enhances antitumor immune responses. Nat Biotechnol 27: 925-932.
36. Kortylewski M, Kujawski M, Wang T, Wei S, Zhang S, et al. (2005) Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity. Nat Med 11: 1314-1321.
37. Yu H, Kortylewski M, Pardoll D, (2007) Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat Rev Immunol 7: 41-51.
38. Yu H, Pardoll D, Jove R, (2009) STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer 9: 798-809.
39. Niu G, Wright KL, Ma Y, Wright GM, Huang M, et al. (2005) Role of Stat3 in regulating p53 expression and function. Mol Cell Biol 25: 7432-7440.
40. Teodoro JG, Parker AE, Zhu X, Green MR, (2006) p53-mediated inhibition of angiogenesis through up-regulation of a collagen prolyl hydroxylase. Science 313: 968-971.
41. Lee H, Zhang P, Herrmann A, Yang C, Xin H, et al. (2012) Acetylated STAT3 is crucial for methylation of tumor-suppressor gene promoters and inhibition by resveratrol results in demethylation. Proc Natl Acad Sci U S A 109: 7765-7769.
42. Yu H, Jove R, (2004) The STATs of cancer-new molecular targets come of age. Nat Rev Cancer 4: 97-105.
43. Kujawski M, Zhang C, Herrmann A, Reckamp K, Scuto A, et al. (2010) Targeting STAT3 in adoptively transferred T cells promotes their in vivo expansion and antitumor effects. Cancer Res 70: 9599-9610.
44. Freeman MR, Schneck FX, Gagnon ML, Corless C, Soker S, et al. (1995) Peripheral blood T lymphocytes and lymphocytes infiltrating human cancers express vascular endothelial growth factor: a potential role for T cells in angiogenesis. Cancer Res 55: 4140-4145.
45. Wong SC, Puaux AL, Chittezhath M, Shalova I, Kajiji TS, et al. (2010) Macrophage polarization to a unique phenotype driven by B cells. Eur J Immunol 40: 2296-2307.
46. Schioppa T, Moore R, Thompson RG, Rosser EC, Kulbe H, et al. (2011) B regulatory cells and the tumor-promoting actions of TNF-alpha during squamous carcinogenesis. Proc Natl Acad Sci U S A 108: 10662-10667.
47. Harada T, Kyttaris V, Li Y, Juang YT, Wang Y, et al. (2007) Increased expression of STAT3 in SLE T cells contributes to enhanced chemokine-mediated cell migration. Autoimmunity 40: 1-8.
48. Prado C, de Paz B, Gomez J, Lopez P, Rodriguez-Carrio J, et al. (2011) Glucocorticoids enhance Th17/Th1 imbalance and signal transducer and activator of transcription 3 expression in systemic lupus erythematosus patients. Rheumatology (Oxford) 50: 1794-1801.
49. Sabahi R, Anolik JH, (2006) B-cell-targeted therapy for systemic lupus erythematosus. Drugs 66: 1933-1948.
50. Tangye SG, Cook MC, Fulcher DA, (2009) Insights into the role of STAT3 in human lymphocyte differentiation as revealed by the hyper-IgE syndrome. J Immunol 182: 21-28.
51. DiMartino SJ, Yuan W, Redecha P, Ivashkiv LB, Salmon JE, (2008) Insoluble immune complexes are most effective at triggering IL-10 production in human monocytes and synergize with TLR ligands and C5a. Clin Immunol 127: 56-65.
52. Maloney DG, (2012) Anti-CD20 antibody therapy for B-cell lymphomas. N Engl J Med 366: 2008-2016.
53. Bartok B, Silverman GJ, (2011) Development of anti-CD20 therapy for multiple sclerosis. Exp Cell Res 317: 1312-1318.